The Amazing Race: Next-Gen Immuno-Oncology Edition

After several false starts and recent missteps, two promising new immuno-oncology classes could soon complement the reigning champions. At ASCO 2020, Roche/Genentech created buzz for their anti-TIGIT candidate. More recently, BMS upped the ante by announcing positive results for its anti-LAG-3 asset.

In this paper, Eric Blouin, Ipsos Healthcare SVP Oncology Research, analyzes the strengths and weaknesses of each class, and anticipates how the race might play out and what its impact on the cancer landscape could be. Unlike most contests, this one could have more than one winner!

Eric started his pharmaceutical career at Sandoz (Novartis) in Clinical Research, where he also worked on Phase IV post-approval studies and New Product Planning role. He has broad global experience in oncology research across solid tumors and hematological malignancies. Eric has worked extensively with targeted therapies and immunotherapies, as well as the emerging cell therapy field.

Download his paper today!